



3R MATRIX

	+	=	-
Right Sector (RS)	Green	Grey with check	Red
Right Quality (RQ)	Green	Grey	Red
Right Valuation (RV)	Green	Grey	Red

+ Positive = Neutral - Negative

What has changed in 3R MATRIX

	Old		New
RS	Grey	↔	Grey
RQ	Green	↔	Green
RV	Green	↔	Green

ESG Disclosure Score

NEW

ESG RISK RATING	35.50			
Updated Mar 08, 2023				
High Risk				
NEGL	LOW	MED	HIGH	SEVERE
0-10	10-20	20-30	30-40	40+

Source: Morningstar

Company details

Market cap:	Rs. 1,22,855 cr
52-week high/low:	Rs. 88/65
NSE volume: (No of shares)	111 lakh
BSE code:	530965
NSE code:	IOC
Free float: (No of shares)	684.9 cr

Shareholding (%)

Promoters	51.5
FII	6.9
DII	11.9
Others	29.7

Price chart



Price performance

(%)	1m	3m	6m	12m
Absolute	12.7	8.0	25.9	4.9
Relative to Sensex	9.3	6.5	25.6	(9.1)

Sharekhan Research, Bloomberg

Indian Oil Corporation Ltd

Stellar Q4; valuation attractive & high dividend yield

Oil & Gas

Sharekhan code: IOC

Reco/View: Buy



Upgrade



Maintain

CMP: Rs. 87

Price Target: Rs. 100



Downgrade

Summary

- Q4FY23 PAT of Rs. 10,059 crore (versus just Rs. 448 crore in Q3FY23) was significantly above our estimate due to a sharp beat in GRMs. Turnaround in the petchem segment, a forex gain of Rs. 989 crore and positive auto fuel marketing margin also contributed to strong earnings.
- GRM at \$15.3/bbl was better than that of HPCL at \$14/bbl and above our estimate of \$11.5/bbl. Refining throughput/pipeline throughput/petchem sales volume at 19 mmt/25mmt/0.7mmt was up by 5%/6%/81% q-o-q.
- We expect earnings to normalise over FY24-25 led by normalisation of crude oil prices. However, a spike in crude oil prices (from \$74-75/bbl currently) is a key risk to earnings recovery especially given OMCs inability to hike petrol/diesel price given general election expected to be scheduled in May 2024.
- We maintain a Buy on IOCL with a revised PT of Rs. 100 on inexpensive valuation of 4.8x/0.8x FY25E EPS/BV and FY24E dividend yield of ~10%.

Indian Oil Corporation Limited's (IOCL) Q4FY23 standalone operating profit came in at Rs. 15,340 crore (up 4.3x q-o-q) was 8% above our estimate of Rs. 14,217 crore led by higher-than-expected derived GRM of \$15.2/bbl (up 18.2% q-o-q and versus our estimate of \$11.5/bbl). We believe that the strong earnings recovery was led by positive auto fuel marketing margin, continued strength in refining margin, turnaround of the petchem business (positive EBIT of Rs. 295 crore versus EBIT loss of Rs. 616 crore in Q3FY23) and forex gain of Rs. 989 crore (versus forex loss of Rs. 1700 crore in Q3FY23). Volume performance was strong with 5%/6%/81% q-o-q rise in refining throughput/pipeline throughput/petchem sales volume at 19mmt/25mmt/0.7mmt, beating our estimate by 2%/8%/50% while marketing sales volume of 22.5 mmt (down 1% q-o-q) was 3% below our estimate. Standalone PAT of Rs. 10,059 crore (versus only Rs. 448 crore) was 36% above estimate led by strong refining & marketing margin, sharp recovery in petchem EBIT, higher-than-expected other income (up 72% y-o-y), lower depreciation/interest cost as well as lower tax rate of 17.7% (versus assumption of 25%).

Key positives

- Higher-than-expected GRM at \$15.3/bbl (up 18% q-o-q) versus estimate of \$11.5/bbl.
- Turnaround in petchem segment with positive EBIT of Rs. 295 crore versus EBIT loss of Rs. 616 crore in Q3FY23.
- IOCL is the only OMC to declare dividend in FY23 (DPS of Rs3/share).

Key negatives

- Decline in market share of petrol/diesel market sales by 41/135 bps q-o-q to 40.1%/43.4%.

Revision in estimates – We have lowered our FY24-25 earnings estimate by 6-7% to factor FY23 P&L and balance sheet numbers and slightly lower GRM assumption.

Our Call

Valuation – Maintain Buy on IOCL with a revised PT of Rs. 100: Normalisation of crude oil prices (recently fell to \$74-75/bbl) and a potential recovery in GRMs would drive earnings revival for IOCL over FY24-25 to normalise PAT of Rs. 23,000-25,000 crore as seen in FY22. IOCL's valuation of 0.8x its FY2025E P/BV and 4.8x its FY2025E EPS is attractive, and the stock offers a high dividend yield (~10% on FY24E DPS). Potential monetisation of non-core assets (hydrogen plant) could unlock value. Hence, we maintain a Buy on IOCL with a revised PT of Rs. 100 (an increase in PT reflects rollover of PE multiple to FY25E EPS).

Key Risks

Sustained weak auto fuel marketing margins in case of the continued inability to raise petrol/diesel prices and lower-than-expected refining margins remain a key risk to earnings and valuation.

Valuation (Standalone)

Particulars	FY22	FY23	FY24E	FY25E
Revenue	5,98,164	8,39,472	7,84,473	8,17,109
OPM (%)	7.2%	2.7%	5.9%	6.2%
Adjusted PAT	24,184	8,242	23,107	25,388
(%) YoY Growth	38.8	-65.9	180.4	9.9
Adjusted EPS (Rs.)	171	5.8	16.4	18.0
P/E (x)	5.1	14.9	5.3	4.8
P/B (x)	0.9	0.9	0.9	0.8
EV/EBITDA (x)	5.4	11.4	5.7	5.4
RoNW (%)	20.0	6.2	16.6	17.1
ROCE (%)	15.1	6.0	12.9	13.4

Source: Company; Sharekhan estimates

Robust Q4; Sharp PAT beat of 36% led by higher GRM, rise in other income & lower tax rate

Q4FY23 standalone operating profit came in at Rs. 15,340 crore (up 4.3x q-o-q) was 8% above our estimate of Rs. 14,217 crore led by higher-than-expected derived GRM of \$15.2/bbl (up 18.2% q-o-q and versus our estimate of \$11.5/bbl). We believe that the strong earnings recovery was led by positive auto fuel marketing margin, continued strength in refining margin, turnaround of the petchem business (positive EBIT of Rs. 295 crore versus EBIT loss of Rs. 616 crore in Q3FY23) and forex gain of Rs. 989 crore (versus forex loss of Rs. 1700 crore in Q3FY23). Volume performance was strong with 5%/6%/81% q-o-q rise in refining throughput/pipeline throughput/petchem sales volume at 19mmt/25mmt/0.7mmt, beating our estimate by 2%/8%/50% while marketing sales volume of 22.5 mmt (down 1% q-o-q) was 3% below our estimate. Standalone PAT of Rs. 10,059 crore (versus only Rs. 448 crore) was 36% above estimate led by strong refining & marketing margin, sharp recovery in petchem EBIT, higher-than-expected other income (up 72% y-o-y), lower depreciation/interest cost as well as lower tax rate of 17.7% (versus assumption of 25%).

Results (Standalone)

Particulars	Rs cr				
	Q4FY23	Q4FY22	YoY (%)	Q3FY23	QoQ (%)
Revenue	2,02,994	1,77,287	14.5	2,04,740	-0.9
Total Expenditure	1,87,654	1,65,660	13.3	2,01,147	-6.7
Operating profit	15,340	11,628	31.9	3,593	326.9
Other Income	1638	952	72.1	1715	-4.5
Interest	1,812	1,607	12.7	1,953	-7.2
Depreciation	2,952	2,887	2.2	3,099	-4.8
PBT	12,215	8,085	51.1	257	4,659.4
Tax	2,156	2,063	4.5	-191	NA
Reported PAT	10,059	6,022	67.0	448	2,145.2
Equity Cap (cr)	941	941		941	
Reported EPS (Rs.)	10.7	6.4	67.0	0.5	2,145.2
Margins (%)			BPS		BPS
OPM	7.6	6.6	99.8	1.8	580.2
NPM	5.0	3.4	155.8	0.2	473.6
Tax rate	17.7	25.5	-786.2	-74.6	9,221.3

Source: Company, Sharekhan Research

Key operating performance

Operating performance	Q4FY23	Q4FY22	YoY (%)	Q3FY23	QoQ (%)
Reported GRM (\$/bbl)	15.3	18.5	-17.6	12.9	18.2
Refining throughput (mmt)	19.2	18.3	5.0	18.2	5.4
Petroleum products market sales including exports (mmt)	22.5	21.7	4.0	22.8	-1.1
Petchem sales (mmt)	0.7	0.8	-13.1	0.4	80.7
Pipeline throughput (mmt)	25.3	22.1	14.7	23.8	6.3

Source: Company, Sharekhan Research

Outlook and Valuation

■ Sector View – Improving outlook but inability to hike petrol and diesel prices a concern for OMCs

OMCs' earnings remained stressed in 9MFY23 on two counts – first, sustained high crude oil prices and an inability to hike retail petrol/diesel prices that would mean large marketing losses on auto fuels and second, refining margins have declined sharply due to lower transportation fuel crack spreads. Moreover, a weakening Indian Rupee would add to trouble given a rise in forex losses. OMCs' inability to hike petrol and diesel prices also remains a concern. However, we believe that the recent decline in the Brent crude price, a likely recovery in refining to mid-cycle level and normalization of marketing margins would drive recovery in earnings of OMCs over FY24-FY25.


■ Company Outlook – Expect gradual earnings recovery

After a weak performance for 9MFY23, IOCL's Q4FY23 earnings performance provides signs of a gradual earnings recovery if crude oil prices remain in a stable-to-declining trend. We believe that core earnings of IOCL to largely normalise from over FY24-25 supported by recovery in refining margin and marketing margins (declining auto fuel under-recoveries and expectations of positive auto fuel marketing margin) and turnaround of the petchem segment. Likely normalisation of international crude oil prices and stable-to-recovering GRMs hold the key for an earnings revival for OMCs.

■ Valuation – Maintain Buy on IOCL with a revised PT of Rs. 100

Normalisation of crude oil prices (recently fell to \$74-75/bbl) and a potential recovery in GRMs would drive earnings revival for IOCL over FY24-25 to normalise PAT of Rs. 23,000-25,000 crore as seen in FY22. IOCL's valuation of 0.8x its FY2025E P/BV and 4.8x its FY2025E EPS is attractive, and the stock offers a high dividend yield (~10% on FY24E DPS). Potential monetisation of non-core assets (hydrogen plant) could unlock value. Hence, we maintain a Buy on IOCL with a revised PT of Rs. 100 (an increase in PT reflects rollover of PE multiple to FY25E EPS).

One-year forward P/E (x) band



Source: Sharekhan Research

About the company

IOCL is a leader in the domestic downstream oil sector with non-replicable infrastructure – total refining capacity of 81 mmt (32% market share; owns 11 of 22 refineries in India), retail outlets of 34,559, and pipeline capacity of 93.1 mmt. The company is also a market leader in domestic petroleum sales with volume of 89 mmt, besides owning a petrochemicals plant at Panipat (with naphtha cracker capacity of 1.46 mmt, LAB capacity of 0.12 mmt, and PX/PTA capacity of 0.5 mmt).

Investment theme

IOCL has diversified earnings with exposure to pipeline and petrochemicals, which insulated it from volatility in refining and marketing margins. Monetisation of hydrogen plant could unlock value for IOCL. Moreover, IOCL's valuation is attractive, and the stock offers a high dividend yield.

Key Risks

- ◆ Lower-than-expected refining and marketing margins could affect earnings outlook.
- ◆ Lower-than-expected volume in case of economic slowdown.
- ◆ Volatility in quarterly earnings in case of fluctuations in oil prices and INR-USD rate.

Additional Data

Key management personnel

Shrikant Madhav Vaidya	Chairman
Sanjay Kaushal	Director – Finance
V Satish Kumar	Director – Marketing

Source: Bloomberg

Top 10 shareholders

Sr. No.	Holder Name	Holding (%)
1	Oil & Natural Gas Corp Ltd	14.2
2	Life Insurance Corp of India	8.4
3	Oil India Ltd	5.2
4	IOC SHARES TRUST	2.5
5	Vanguard Group Inc/The	1.1
6	SBI Funds Management Ltd	1.0
7	BlackRock Inc	0.8
8	ICICI Prudential Asset Management	0.5
9	Norges Bank	0.3
10	Charles Schwab Corp/The	0.2

Source: Bloomberg

Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.

Understanding the Sharekhan 3R Matrix

Right Sector	
Positive	Strong industry fundamentals (favorable demand-supply scenario, consistent industry growth), increasing investments, higher entry barrier, and favorable government policies
Neutral	Stagnancy in the industry growth due to macro factors and lower incremental investments by Government/private companies
Negative	Unable to recover from low in the stable economic environment, adverse government policies affecting the business fundamentals and global challenges (currency headwinds and unfavorable policies implemented by global industrial institutions) and any significant increase in commodity prices affecting profitability.
Right Quality	
Positive	Sector leader, Strong management bandwidth, Strong financial track-record, Healthy Balance sheet/cash flows, differentiated product/service portfolio and Good corporate governance.
Neutral	Macro slowdown affecting near term growth profile, Untoward events such as natural calamities resulting in near term uncertainty, Company specific events such as factory shutdown, lack of positive triggers/events in near term, raw material price movement turning unfavourable
Negative	Weakening growth trend led by led by external/internal factors, reshuffling of key management personal, questionable corporate governance, high commodity prices/weak realisation environment resulting in margin pressure and deteriorating balance sheet
Right Valuation	
Positive	Strong earnings growth expectation and improving return ratios but valuations are trading at discount to industry leaders/historical average multiples, Expansion in valuation multiple due to expected outperformance amongst its peers and Industry up-cycle with conducive business environment.
Neutral	Trading at par to historical valuations and having limited scope of expansion in valuation multiples.
Negative	Trading at premium valuations but earnings outlook are weak; Emergence of roadblocks such as corporate governance issue, adverse government policies and bleak global macro environment etc warranting for lower than historical valuation multiple.

Source: Sharekhan Research

DISCLAIMER

This information/document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This information/ document is subject to changes without prior notice.

Recommendation in reports based on technical and derivatives analysis is based on studying charts of a stock's price movement, trading volume, outstanding positions, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals. However, this would only apply for information/document focused on technical and derivatives research and shall not apply to reports/documents/information focused on fundamental research.

This information/document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this information/report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other recommendations/ reports that are inconsistent with and reach different conclusions from the information presented in this recommendations/report.

This information/recommendation/report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst might have dealt or traded directly or indirectly in securities of the company and that all the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst and SHAREKHAN further certifies that either he or his relatives or Sharekhan associates might have direct or indirect financial interest or might have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report. The analyst and SHAREKHAN encourages independence in research report/material preparation and strives to minimize conflict in preparation of research report. The analyst and SHAREKHAN does not have any material conflict of interest or has not served as officer, director or employee or engaged in market making activity of the company. The analyst and SHAREKHAN has not been a part of the team which has managed or co-managed the public offerings of the company, and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Ltd or its associates or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from third party in the past twelve months in connection with the research report.

Either SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Forward-looking statements (if any) are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not a guarantee of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. Sharekhan/its affiliates undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader/investors are cautioned not to place undue reliance on forward-looking statements and use their independent judgement before taking any investment decision.

Investment in securities market are subject to market risks, read all the related documents carefully before investing. The securities quoted are for illustration only and are not recommendatory. Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on www.sharekhan.com

Registration and Contact Details: Name of Research Analyst - Sharekhan Limited, Research Analyst Regn No.: INH000006183. (CIN): - U99999MH1995PLC087498. Registered Office: The Ruby, 18th Floor, 29 Senapati Bapat Marg, Dadar (West), Mumbai – 400 028, Maharashtra, INDIA. Tel: 022-6115000.

Other registrations of Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE / MSEI (CASH / F&O / CD) / MCX - Commodity: INZ000171337; DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669.

Compliance Officer: Ms. Binkle Oza; Tel: 022-61169602; email id: complianceofficer@sharekhan.com

For any complaints/grievance, email us at igc@sharekhan.com or you may even call Customer Service desk on - 022- 41523200/022- 33054600